About Cordlife
Cordlife is a publicly listed company based in Singapore (Singapore) founded in 2001. Cordlife is engaged in cord blood banking and diagnostics. It operates on a Subscription Services and Professional Services model. Cordlife has raised $7 million across 1 funding round from investors including Rothschild, APC Investors and UOB Venture Management. Cordlife has completed 1 acquisition, including StemLife. Its website cordlife.com draws about 14 thousand monthly visits. Cordlife offers products and services including Cord Blood Banking, Cord Lining Banking, Cord Tissue Banking, Non-Invasive Prenatal Testing, and Newborn Metabolic Screening. Its focus areas include Biotechnology and Stem Cell Banking. Its legal entity is Cordlife Group Limited.
Company details
Cordlife Group Limited is focused on safeguarding the well-being of mother and child through private cord blood banking and related healthcare services. Operating primarily in Asia, the company is recognized as a pioneer in stem cell banking with facilities in Singapore, Hong Kong, Indonesia, the Philippines, India, and Malaysia. A comprehensive suite of diagnostics services, including non-invasive prenatal testing and newborn metabolic screening, is provided alongside cord blood, lining, and tissue banking. Innovation and technological advancement are emphasized to ensure reliable healthcare solutions across its markets.
- Headquarters Singapore, Singapore
- Stage Public
- SectorsHealthcare
- Website cordlife.com
- Social LinkedIn X
- Legal Name Cordlife Group Limited
- Annual Revenue$30.22 M (USD)40.53as on Dec 31, 2025
- Net Profit-$9.83 M (USD)33.06as on Dec 31, 2025
- EBITDA-$8.35 M (USD)46.79as on Dec 31, 2025
- Total Equity Funding$7M (USD)
in 1 rounds
- Latest Funding Round$7M (USD), Series B
Nov 2003
- InvestorsRothschild
& 2 more
- Investments & Acquisitions
Products & Services of Cordlife
Cordlife offers a comprehensive portfolio of products and services, including Cord Blood Banking, Cord Lining Banking, Cord Tissue Banking, Non-Invasive Prenatal Testing, and Newborn Metabolic Screening.
Cord blood is stored for future medical use.
Cord lining is preserved for potential therapeutic applications.
Cord tissue is banked for future regenerative treatments.
Prenatal testing is offered for early health insights.
Metabolic screening is provided for newborn health checks.
Funding Insights of Cordlife
Cordlife has successfully raised a total of $7M through 1 strategic funding round. The most recent funding activity was a Series B round of $7 million completed in November 2003. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7M
- Total Rounds 1
- Last Round Series B — $7M
- First Round $7M
(Nov 2003)
- Investors Count 3
All 1 funding rounds of Cordlife with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2003 | $7M | Series B | – | – |
3 investors in total: 3 institutional.
Investors in Cordlife
Cordlife has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Rothschild, APC Investors and UOB Venture Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Limited information is provided about UOB Venture Management. | uobvm.com.sg | Singapore, Singapore | ||
Manages diversified investment portfolios across multiple asset classes for clients. | 1992 | apcinvestors.com | Hong Kong, China | |
Global investment banking services are provided worldwide. | 1811 | rothschild.com | Paris, France |
Investor details for Cordlife
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cordlife
9 people are tracked at Cordlife (9 in leadership).
| Name | Role | Group |
|---|---|---|
Dang Vinh Do | Deputy Laboratory And Technical Director | Leadership |
Arvin C. Faundo | Medical Director | Leadership |
Prosanto Kumar Chowdhury | Laboratory Director | Leadership |
Kevin K.w. Chik | Medical Director | Leadership |
Elaine Ng | Marketing Manager (head Of Marketing) | Leadership |
Chiew Yoke Fong | Medical Director | Leadership |
Leung Ho Chuen | Deputy Laboratory And Technical Director | Leadership |
Cheryl Tiuseco | Assistant Medical Director | Leadership |
Zhu Peng Cheng | Laboratory And Technical Director | Leadership |
Complete people profiles for Cordlife
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Cordlife
Cordlife is a publicly listed company on the SGX with ticker symbol P8A in Singapore, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date29 Mar 2012
- Listed on SGX: P8A
- Listed entityCordlife Group Limited
- Exchange sectorHealth services
- ISINSG2E64980112
- Share price0.12 SGD · 2026-10-12
- Market capitalisation30,891,476.00 SGD
- EPS (diluted, trailing year)-0.04 SGD
- Volume (last session)5,000
Financials of Cordlife
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 38.9M SGD | -12.6M SGD | -10.7M SGD |
| 2024 | 27.6M SGD | -18.9M SGD | -20.2M SGD |
| 2023 | 55.7M SGD | 3.5M SGD | 3.0M SGD |
| 2022 | 55.2M SGD | 4.9M SGD | 4.6M SGD |
| 2021 | 56.7M SGD | 6.1M SGD | 7.1M SGD |
Detailed financial statements for Cordlife
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cordlife
Cordlife has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include StemLife.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Cord blood and tissue banking, plus genetic testing, is provided. | stemlife.com | Kuala Lumpur, Malaysia | 2001 | Nov 2015 | $17.1M |
Complete acquisition details for Cordlife
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Cordlife
4 dated milestones of Cordlife across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Cordlife is founded.
- Funding First funding round of $7.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires StemLife.
Web traffic of Cordlife
The website of Cordlife (cordlife.com) receives about 14K visits a month.
- Monthly visits14K
▼ 10.3% vs previous month
Websites whose visitors overlap most with Cordlife. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
parentsguidecordblood.org | parentsguidecordblood.org | 100% | #598,338 | – | |
| cordlifeindia.com | 88% | 24.5K | #1,076,337 | View details | |
jeevan.org | jeevan.org | 84% | – | ||
parenting.co.id | parenting.co.id | 83% | #10,133,520 | – | |
motherandbaby.co.id | motherandbaby.co.id | 61% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for Cordlife
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cordlife
Complete news archive for Cordlife
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cordlife
Cordlife was founded in 2001 and raised its 1st funding round 2 years after it was founded.
Cordlife is headquartered in Singapore, Singapore.
Cordlife is a funded company, having raised a total of $7M across 1 funding round to date. The company's 1st funding round was a Series B of $7M, raised on Nov 2003.
Annual revenue of Cordlife is $30.22M as on Dec 31, 2025.
Cordlife Group Limited is focused on safeguarding the well-being of mother and child through private cord blood banking and related healthcare services. Operating primarily in Asia, the company is recognized as a pioneer in stem cell banking with facilities in Singapore, Hong Kong, Indonesia, the Philippines, India, and Malaysia. A comprehensive suite of diagnostics services, including non-invasive prenatal testing and newborn metabolic screening, is provided alongside cord blood, lining, and tissue banking. Innovation and technological advancement are emphasized to ensure reliable healthcare solutions across its markets.
Cordlife offers Cord Blood Banking, Cord Lining Banking, Cord Tissue Banking, Non-Invasive Prenatal Testing, and Newborn Metabolic Screening.
Yes, Cordlife is publicly traded on SGX under the ticker symbol P8A.
Cordlife has made 1 acquisition, including StemLife.
Cordlife has 3 investors. Key investors include Rothschild, APC Investors, and UOB Venture Management.
Cordlife operates through Cordlife Group Limited.